Ketamine (drug)

Ketamine (drug)
source
Name	Ketamine
Tradename	Ketalar, Ketaset, Ketalar-50
Legal AU	S4
Legal CA	Schedule I
Legal UK	Class B
Legal US	Schedule III
Routes of administration	Intravenous, intramuscular, intranasal, oral, sublingual
Bioavailability	90% (IV), 93% (IM), 25% (intranasal), 20% (oral)
Protein bound	~12%
Metabolism	Hepatic, CYP2B6, CYP3A4, CYP2C9
Onset	30–60 seconds (IV)
Elimination half-life	3 hours
Excretion	Renal

Ketamine (drug) is a dissociative anesthetic used in human and veterinary medicine for induction and maintenance of anesthesia, analgesia, and procedural sedation. It is also used off-label and in research contexts for treatment-resistant depression, chronic pain, and acute suicidality. Developed in the mid-20th century, ketamine has a complex regulatory, clinical, and cultural history that intersects with Food and Drug Administration, World Health Organization, and varied national medicines agencies.

Medical Uses

Ketamine is approved for induction and maintenance of anesthesia in adults and children by the Food and Drug Administration and is included on the World Health Organization Model List of Essential Medicines. In emergency medicine and prehospital care, ketamine provides hemodynamic stability during induction for patients with hypotension; it is used by American College of Emergency Physicians and many National Health Service protocols for rapid sequence intubation, analgesia, and procedural sedation. For chronic pain, ketamine infusions are administered in specialized centers and by pain specialists certified through associations such as the American Academy of Pain Medicine and International Association for the Study of Pain. Intranasal esketamine, an S-enantiomer formulation, has regulatory approval for treatment-resistant depression and acute suicidal ideation through agencies like the European Medicines Agency and the Food and Drug Administration. Off-label psychiatric use has been guided by bodies including the American Psychiatric Association and academic centers at institutions such as Massachusetts General Hospital and Johns Hopkins University.

Pharmacology

Ketamine acts primarily as a noncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, a mechanism elucidated in studies from laboratories at institutions like Columbia University and University College London. It also interacts with opioid receptors, monoaminergic systems, and glutamate transmission pathways investigated at centers such as Harvard Medical School and Yale School of Medicine. The S-(+)-enantiomer (esketamine) exhibits greater affinity at NMDA receptors and different pharmacodynamic profiles compared with (R)-(−)-ketamine, a distinction explored in research from Stanford University and University of Oxford. Cytochrome P450 enzymes including CYP2B6, CYP3A4, and CYP2C9 mediate hepatic metabolism to active metabolites such as norketamine; pharmacokinetic modeling has been advanced by groups at University of California, San Francisco and Karolinska Institutet.

Chemistry and Formulations

Chemically, ketamine is a cyclohexanone derivative synthesized originally by laboratories led by Parke-Davis researchers working in the 1960s. Structural and stereochemical analyses have been published in journals associated with American Chemical Society and Royal Society of Chemistry researchers. Pharmaceutical formulations include racemic ketamine hydrochloride for injection, intranasal sprays of esketamine developed by companies like Janssen Pharmaceuticals, and compounded oral or sublingual preparations used in pain clinics; compounding is regulated by national authorities such as the U.S. Pharmacopeia and European Directorate for the Quality of Medicines. Veterinary formulations (e.g., Ketaset) are produced for use in settings from Royal Veterinary College clinics to wildlife management programs administered by institutions like Smithsonian Institution.

Adverse Effects and Safety

Common acute adverse effects include dissociation, hallucinations, increased heart rate, and elevated blood pressure, observed in emergency departments at institutions such as Mayo Clinic and Cleveland Clinic. Neuropsychiatric sequelae and emergence phenomena have been characterized in studies from Columbia University and University of Toronto; benzodiazepine premedication is sometimes used per protocols recommended by the American Society of Anesthesiologists. Chronic high-dose exposure has been associated with urinary tract dysfunction (ketamine cystitis) documented in case series from hospitals in Hong Kong, United Kingdom, and Australia. Hepatic injury and cognitive effects have been reviewed by panels convened at the National Institutes of Health and regional health agencies. Safety in pregnancy and breastfeeding is addressed by guidance from organizations including the American College of Obstetricians and Gynecologists.

Addiction, Misuse, and Legal Status

Ketamine has recognized potential for recreational misuse and dependence, with patterns documented by surveillance systems such as the United Nations Office on Drugs and Crime and the European Monitoring Centre for Drugs and Drug Addiction. Legal scheduling varies: it is Schedule III in the United States (regulated by the Drug Enforcement Administration), Class B in the United Kingdom (Home Office), and controlled or prescription-only in jurisdictions overseen by agencies like Health Canada and the Therapeutic Goods Administration of Australia. Harm-reduction initiatives and public health responses have involved organizations such as UNAIDS, World Health Organization, and local addiction services run by entities like NHS England and municipal public health departments.

Historical Development and Society

Ketamine was synthesized in the 1960s by researchers at Parke-Davis as part of a search for safer anesthetics following the clinical use of agents promoted by researchers at Harvard Medical School and others. It gained rapid adoption in military medicine, including use by forces involved in conflicts documented by institutions like the U.S. Department of Defense and NATO medical services. Cultural visibility increased through reports in media outlets such as BBC and The New York Times, and it became a subject of forensic and legal attention in cases handled by courts like the Supreme Court of the United Kingdom and the United States Court of Appeals. Advocacy groups and patient organizations, including chapters affiliated with Depression and Bipolar Support Alliance and research foundations at Salk Institute, have influenced policy and research funding priorities.

Research and Emerging Applications

Ongoing research examines mechanisms and clinical efficacy for mood disorders at centers such as National Institute of Mental Health, Mount Sinai Health System, and Columbia University. Trials of ketamine and esketamine for posttraumatic stress disorder, bipolar depression, and chronic neuropathic pain are registered with organizations including ClinicalTrials.gov and coordinated by academic consortia involving University of Pennsylvania and McLean Hospital. Translational research into metabolites (e.g., hydroxynorketamine) and novel delivery systems is conducted at laboratories affiliated with Scripps Research Institute and Massachusetts Institute of Technology. Ethical and regulatory frameworks for clinical use are being developed by professional societies such as the American Psychiatric Association and regulatory bodies including the European Medicines Agency.

Category:Anesthetics Category:Psychopharmacology